Exelixis

Exelixis EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Exelixis (EXEL) as of Nov 15, 2026 is 12.29. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 17.72 — a change of -30.68% (lower).

EV/EBIT

12.29

YoY

-30.68%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Exelixis is 2025 12.29 . EV/EBIT (Enterprise Value to EBIT) of Exelixis was 2024 17.72 . It decreases by -30.68% lower compared to the previous year.

The Exelixis EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
29.00 USD
Jan 1, 2020
97.36 USD
Jan 1, 2021
37.38 USD
Jan 1, 2022
53.18 USD
Jan 1, 2023
62.71 USD
Jan 1, 2024
17.72 USD
Jan 1, 2025
12.29 USD
Jan 1, 2026 (e)
14.83 USD
The Exelixis EV/EBIT history
YEAREV/EBITYoY
est14.83+20.71%
12.29-30.68%
17.72-71.74%
62.71+17.91%
53.18+42.28%
37.38-61.61%
97.36+235.70%
29.00+18.78%
24.42-62.19%
64.59-116.95%
-381.01+331.73%
-88.25+84.86%
-47.74+3,040.78%
-1.52-9.52%
-1.68-190.81%
1.85-217.09%
-1.58+50.48%
-1.05+118.75%
-0.48-45.45%
-0.88-11.11%
-0.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Exelixis's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Exelixis's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Exelixis's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Exelixis grows earnings faster than its peers.

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

EV/EBIT (Enterprise Value to EBIT) of Exelixis is 12.29 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Exelixis changed from 17.72 to 12.29, representing a -30.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Exelixis since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Exelixis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Exelixis

All Key Metrics — Exelixis